Antigen delivery by α2-macroglobulin enhances the cytotoxic T lymphocyte response
Open Access
- 3 August 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 86 (5) , 1259-1268
Abstract
α-2M*-mediated antigen delivery leads to cross-presentation and improved cell-mediated immunity, suggesting that α-2M* may have applications for vaccines based on weakly immunogenic subunits.α2M* targets antigens to APCs for rapid internalization, processing, and presentation. When used as an antigen-delivery vehicle, α2M* amplifies MHC class II presentation, as demonstrated by increased antibody titers. Recent evidence, however, suggests that α2M* encapsulation may also enhance antigen-specific CTL immunity. In this study, we demonstrate that α2M*-delivered antigen (OVA) enhances the production of specific in vitro and in vivo CTL responses. Murine splenocytes expressing a transgenic TCR specific for CTL peptide OVA257–264 (SIINFEKL) demonstrated up to 25-fold greater IFN-γ and IL-2 secretion when treated in vitro with α2M*-OVA compared with soluble OVA. The frequency of IFN-γ-producing cells was increased ∼15-fold, as measured by ELISPOT. Expansion of the OVA-specific CD8+ T cell population, as assayed by tetramer binding and [3H]thymidine incorporation, and OVA-specific cell-mediated cytotoxicity, as determined by a flow cytometric assay, were also enhanced significantly by α2M*-OVA. Furthermore, significant CTL responses were observed at antigen doses tenfold lower than those required with OVA alone. Finally, we also observed enhanced humoral and CTL responses by naïve mice following intradermal immunization with α2M*-OVA. These α2M*-OVA-immunized mice demonstrated increased protection against a s.c.-implanted, OVA-expressing tumor, as demonstrated by delayed tumor growth and prolonged animal survival. The observation that α2M*-mediated antigen delivery elicits specific CTL responses suggests the cross-presentation of antigen onto MHC class I. These results support α2M* as an effective antigen-delivery system that may be particularly useful for vaccines based on weakly immunogenic subunits or requiring dose sparing.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (#HL-24066)
This publication has 33 references indexed in Scilit:
- α2-Macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanismJournal of Leukocyte Biology, 2007
- Interferon-γ: an overview of signals, mechanisms and functionsJournal of Leukocyte Biology, 2003
- The Role of Grp 78 in α2-Macroglobulin-induced Signal TransductionJournal of Biological Chemistry, 2002
- Increased immunogenicity of HIV envelope subunit complexed with α2-macroglobulin when combined with monophosphoryl lipid A and GM-CSFVaccine, 2002
- Covalent complexes of antigen and α2-macroglobulin: evidence for dramatically-increased immunogenicityVaccine, 2001
- Incorporation of non-proteolytic proteins by murine α2-macroglobulinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1999
- Nonproteolytic Incorporation of Protein Ligands into Human α2-Macroglobulin: Implications for the Binding Mechanism of α2-MacroglobulinBiochemistry, 1998
- α2‐Macroglobulin: A Sensor for ProteolysisAnnals of the New York Academy of Sciences, 1994
- Interactions between cytokines and α2-macroglobulinImmunology Today, 1990
- Trypsin‐induced activation of the thiol esters in α2‐macroglobulin generates a short‐lived intermediate (‘nascent’ α2M) that can react rapidly to incorporate not only methylamine or putrescine but also proteins lacking proteinase activityFEBS Letters, 1981